Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower

Azenta, Inc.

2024-Q2 EPS reported -$2.72 revenue$313,451,000

Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.
GAAP diluted EPS from continuing ops ($2.47) vs ($0.03); includes $111.3M non-cash goodwill impairment in B Medical.
Non-GAAP diluted EPS $0.05 vs ($0.06); adjusted EBITDA $9M vs ($2M); margin 5.9% up 750 bps.
FY2024 rev guidance lowered to $659-$671M (organic -1% to +1%); non-GAAP EPS raised to $0.27-$0.37.
Repurchased 1.2M shares for $73.9M in Q2; $1.025B used of $1.5B authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Azenta, Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $159 million, net income $ (2.47) diluted EPS from continuing operations, EPS $ (2.47) diluted EPS from continuing operations. Guidance lowered.

Period: the fiscal quarter ended March 31, 2024
Revenue: $159 million
Net income: $ (2.47) diluted EPS from continuing operations
EPS: $ (2.47) diluted EPS from continuing operations
Guidance: lowered
Result: reported results

Exact text from the filing

Day in March, we are confident in our position and the market opportunity which we are uniquely positioned to capture.” Second Quarter Fiscal 2024 Results ● Revenue was $159 million, up 7% year over year. Organic revenue, which excludes the impacts from foreign exchange, was also up 7% year over year, with a nominal benefit from foreign exchange tailwinds.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.